CG Oncology (NASDAQ:CGON) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of CG Oncology (NASDAQ:CGON) in a research report released on Monday, Benzinga reports. The brokerage currently has a $75.00 price objective on the stock.

Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed an overweight rating and issued a $75.00 price target on shares of CG Oncology in a report on Thursday, May 2nd. Morgan Stanley assumed coverage on CG Oncology in a report on Tuesday, February 20th. They set an overweight rating and a $55.00 price objective for the company. Finally, The Goldman Sachs Group began coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They issued a neutral rating and a $42.00 price objective on the stock.

CG Oncology Price Performance

Shares of NASDAQ:CGON opened at $35.10 on Monday. The company’s 50 day moving average price is $39.41. CG Oncology has a 12 month low of $28.55 and a 12 month high of $50.23.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new stake in shares of CG Oncology in the 1st quarter valued at $492,000. TimesSquare Capital Management LLC purchased a new stake in CG Oncology during the 1st quarter valued at about $9,837,000. Finally, Capstone Investment Advisors LLC bought a new position in CG Oncology during the 1st quarter worth approximately $806,000. 26.56% of the stock is currently owned by institutional investors.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.